AR019916A1 - Uso de 11-(3-dimetilaminopropiliden)-6,11-dihidrobenz[b,e]oxepin-2-acetico para la manufactura de una formulacion farmaceutica oftalmica util para eltratamiento o prevencion de la neovascularizacion ocular y trastornos inflamatorios oftalmicos no alergicos que involucran la liberacion de citoquinas - Google Patents

Uso de 11-(3-dimetilaminopropiliden)-6,11-dihidrobenz[b,e]oxepin-2-acetico para la manufactura de una formulacion farmaceutica oftalmica util para eltratamiento o prevencion de la neovascularizacion ocular y trastornos inflamatorios oftalmicos no alergicos que involucran la liberacion de citoquinas

Info

Publication number
AR019916A1
AR019916A1 ARP990103415A ARP990103415A AR019916A1 AR 019916 A1 AR019916 A1 AR 019916A1 AR P990103415 A ARP990103415 A AR P990103415A AR P990103415 A ARP990103415 A AR P990103415A AR 019916 A1 AR019916 A1 AR 019916A1
Authority
AR
Argentina
Prior art keywords
opulmergic
oxepin
cytokines
prevention
manufacture
Prior art date
Application number
ARP990103415A
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd, Kyowa Hakko Kogyo Kk filed Critical Alcon Res Ltd
Publication of AR019916A1 publication Critical patent/AR019916A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Uso del 11-(3-dimetilaminopropiliden)-6,11-dihidrobenz[b,e]oxipen-2-acético para la manufactura de una formulacion farmacéutica oftálmica util para eltratamiento o prevencion de la neovascularizacion ocular y trastornos inflamatorios oftálmicos no alérgicos que involucran la liberacion de citoquina decélulas oculares humanas que comprende una cantidad terapéuticamente efectiva de una composicion que comprende el ácido 11-(3-dimetilaminopropiliden)-6,11-dihidrodibenz[b,e]oxepin-2-acético o de susal farmacéuticamente aceptable. Formulaciones oftálmicas que contienen como un ingrediente activo al ácido11-(3-dimetilaminopropilen)-6,11-dihidrobenz[b,e]oxepin-2-acético o de su sal farmacéuticamente aceptable son utiles para inhibir la liberacionde citoquinas(por ejemplo, IL-6 e IL-8) de células oculares humanas. Ese tipo de formulaciones se pueden utilizar para tratar o prevenir la neovascularizacion ocular y lostrastornos inflamatorios no alérgicos como ser sequedad ocular, queratitis, blefaritis, uveítis e inflamacion relacionada con infeccion.
ARP990103415A 1998-07-14 1999-07-13 Uso de 11-(3-dimetilaminopropiliden)-6,11-dihidrobenz[b,e]oxepin-2-acetico para la manufactura de una formulacion farmaceutica oftalmica util para eltratamiento o prevencion de la neovascularizacion ocular y trastornos inflamatorios oftalmicos no alergicos que involucran la liberacion de citoquinas AR019916A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9276298P 1998-07-14 1998-07-14

Publications (1)

Publication Number Publication Date
AR019916A1 true AR019916A1 (es) 2002-03-27

Family

ID=22235027

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103415A AR019916A1 (es) 1998-07-14 1999-07-13 Uso de 11-(3-dimetilaminopropiliden)-6,11-dihidrobenz[b,e]oxepin-2-acetico para la manufactura de una formulacion farmaceutica oftalmica util para eltratamiento o prevencion de la neovascularizacion ocular y trastornos inflamatorios oftalmicos no alergicos que involucran la liberacion de citoquinas

Country Status (18)

Country Link
EP (1) EP1037627B1 (es)
JP (1) JP2002520355A (es)
KR (1) KR100598723B1 (es)
CN (1) CN1114401C (es)
AR (1) AR019916A1 (es)
AT (1) ATE203668T1 (es)
AU (1) AU742237B2 (es)
BR (1) BR9906772A (es)
CA (1) CA2306393C (es)
DE (1) DE69900207T2 (es)
DK (1) DK1037627T3 (es)
ES (1) ES2159209T3 (es)
GR (1) GR3036422T3 (es)
HK (1) HK1030362A1 (es)
PT (1) PT1037627E (es)
TW (1) TW561046B (es)
WO (1) WO2000003705A1 (es)
ZA (1) ZA200001593B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4851035B2 (ja) 1999-06-18 2012-01-11 アルコン ラボラトリーズ，インコーポレイティド アレルギー性眼疾患を処置するための局所的な眼マスト細胞安定剤
US20020077358A1 (en) * 2000-10-23 2002-06-20 Alcon Universal Ltd. Use of hydroperoxyeicosatetraenoic acid derivatives following refractive surgery
PT1392355E (pt) 2001-05-21 2007-03-30 Alcon Inc Utilização de inibidores do proteassoma para tratar distúrbios associados à secura ocular
CN1509462A (zh) * 2001-05-21 2004-06-30 NF-κB抑制剂在治疗干眼疾病中的用途
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
AU2003235454A1 (en) * 2002-06-14 2003-12-31 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
CN103143022A (zh) 2002-07-30 2013-06-12 奥默罗斯公司 眼科冲洗液及方法
WO2004026406A1 (en) 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
WO2004093878A1 (en) * 2003-04-16 2004-11-04 Alcon, Inc. Use of fused pyridazine derivatives for treating dry eye disorders
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7923471B2 (en) 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US7223737B1 (en) 2004-08-13 2007-05-29 Alcon, Inc. Method of treating dry eye disorders using glycosides
DK1881823T3 (en) * 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
CA2646424C (en) 2006-03-17 2015-12-29 Johnson & Johnson Vision Care, Inc. Methods for stabilizing oxidatively unstable compositions
JP2009532132A (ja) 2006-03-31 2009-09-10 キューエルティー プラグ デリバリー，インク． 薬物治療用鼻涙排液系インプラント
RU2010112417A (ru) 2007-09-07 2011-10-10 Клт Плаг Диливери, Инк. (Us) Обнаружение лакримальных имплантатов
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
WO2011057183A1 (en) 2009-11-06 2011-05-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US20190177407A1 (en) 2016-06-20 2019-06-13 Novartis Ag Methods of treating dry eye disease using tnf alpha antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6310784A (ja) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
JPH02138215A (ja) * 1988-08-05 1990-05-28 Dai Ichi Seiyaku Co Ltd 抗アレルギー・抗炎症剤
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
JP3453152B2 (ja) * 1992-04-06 2003-10-06 格 冨山 抗炎症点眼剤
FR2701948B1 (fr) * 1993-02-22 1996-07-26 Exsymol Sa Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires.
DK0690715T3 (da) * 1993-03-26 2003-09-22 Beth Israel Hospital Topisk og systemisk applikation af busphiron eller derivater deraf til behandling af pathologiske tilstande associeret med immunreaktioner
FR2711990B1 (fr) * 1993-11-05 1995-12-08 Exsymol Sa Produit pseudodipeptide possédant un groupement imidazole, et applications thérapeutiques, cosmétologiques et agroalimentaires.
JP2852607B2 (ja) * 1994-06-10 1999-02-03 雪印乳業株式会社 ドライアイ治療剤
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
JPH1067684A (ja) * 1996-06-17 1998-03-10 Mitsubishi Chem Corp 涙液分泌促進剤
CA2272073A1 (en) * 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye

Also Published As

Publication number Publication date
CN1275078A (zh) 2000-11-29
AU742237B2 (en) 2001-12-20
DE69900207T2 (de) 2001-11-22
AU4563499A (en) 2000-02-07
JP2002520355A (ja) 2002-07-09
HK1030362A1 (en) 2001-05-04
EP1037627A1 (en) 2000-09-27
GR3036422T3 (en) 2001-11-30
ATE203668T1 (de) 2001-08-15
WO2000003705A1 (en) 2000-01-27
KR100598723B1 (ko) 2006-07-11
ZA200001593B (en) 2000-10-25
EP1037627B1 (en) 2001-08-01
ES2159209T3 (es) 2001-09-16
DK1037627T3 (da) 2001-10-01
PT1037627E (pt) 2001-11-30
CA2306393A1 (en) 2000-01-27
CA2306393C (en) 2008-12-23
TW561046B (en) 2003-11-11
KR20010024508A (ko) 2001-03-26
CN1114401C (zh) 2003-07-16
BR9906772A (pt) 2000-09-26
DE69900207D1 (de) 2001-09-06

Similar Documents

Publication Publication Date Title
AR019916A1 (es) Uso de 11-(3-dimetilaminopropiliden)-6,11-dihidrobenz[b,e]oxepin-2-acetico para la manufactura de una formulacion farmaceutica oftalmica util para eltratamiento o prevencion de la neovascularizacion ocular y trastornos inflamatorios oftalmicos no alergicos que involucran la liberacion de citoquinas
RU2018119295A (ru) Фармацевтические составы для местного применения для лечения связанных с воспалением состояний
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
DK0799044T3 (da) Topiske oftalmologiske formuleringer indeholdende olopatidin til behandling af allergiske øjensygdomme
US10314914B2 (en) Iodophor composition and methods of use
DE69930259D1 (de) Zusammensetzungen zur anwendung von entzündungshemmenden, insbesondere antiseptischen und/oder wundheilenden wirkstoffen im oberen atemwegtrakt und/oder ohr
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
AR034619A1 (es) Formulaciones de olopatadine para administracion topica
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
PT1534352E (pt) Implante para transporte e libertação de agentes farmacologicamente activos e processo para a sua produção
DK0737475T3 (da) Anvendelse af en muscarin antagonist til fremstilling af et medikament til behandling og regulering af okular udvikling
KR20210010638A (ko) 다이피리다몰을 이용하여 눈 장애를 치료하는데 사용하기 위한 조성물
BR0008054A (pt) Forma cristalina de eplerenona
KR101744895B1 (ko) 미라미스틴을 포함하는 약학적 제제
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
NO20030475D0 (no) Ikke-peptid CCR1 reseptor antagonist i kombinasjon med cyclosporin A for behandling av hjertetransplantatforkastning
AR036194A1 (es) Uso de compuestos para la fabricacion de un medicamento que promueven la regeneracion de las neuronas o de las excrecencias neuriticas para el tratamiento de xeroftalmia y para la diminucion de la sensibilidad de la cornea despues de lasik u otras cirugias cuando los nervios corneales estan lesionad
AR018825A1 (es) Antagonistas del receptor de bradiquinina no peptidica para uso en el tratamiento de trastornos y enfermedades oftalmicas
EP1201243A1 (en) Use of sulfadiazine and sulfadimidine for treating erectile dysfunction

Legal Events

Date Code Title Description
FB Suspension of granting procedure